Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159365 · ClinicalTrials.gov registry record · Phase 2
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT02159365 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 84 participants.
The verdict
NCT02159365, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Elotuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2014-03-08 |
| Est. Completion | 2018-07-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02159365
The ClinicalTrials.gov registry entry for NCT02159365 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02159365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02159365 about?
NCT02159365 is a clinical study titled "Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients". To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.
What is the current status of trial NCT02159365?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2014-03-08. Estimated completion is 2018-07-11.
What interventions are being tested in trial NCT02159365?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Elotuzumab (DRUG).
Who is sponsoring clinical trial NCT02159365?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.